Abstract:Abstract There is a strong correlation between PD-L1 expression and the malignancy of the tumor, and targeted regulation of PD-L1 expression can significantly improve the lung cancer patients' prognosis. The transcriptional regulation of PD-L1 expression is a critical topic in current research. Previous studies have demonstrated that melatonin (MLT) can promote the remote effect of radiofrequency ablation (RFA). However, it is unclear whether this action of MLT is through inhibiting the expression of PD-L1 in tumor cells. Our transcriptomic analysis showed that MLT significantly inhibited the tumor tissue expression of PD-L1 and NRF2 and enhanced the remote effect of RFA ablation. Our subsequent in vitro experiments also demonstrated that MLT could suppress tumor cells by inhibiting the expression of PD-L1 and NRF2. Further study demonstrated that NRF2 could inhibit the transcriptional expression of PD-L1. The dual luciferase reporter assay showed that NRF-2 inhibited the transcription expression of PD-L1 by activating the PD-L1 promoter. Deletion mutation research has shown that the transcriptional regulation of NRF2 is achieved by repressing the activation of TCAGAGGCTAT, a specific locus of the PD-L1 promoter. For the first time, we found that NRF2 was an important transcriptional regulator of PD-L1 promoter, and MLT could promote the remote effect of RFA ablation by inhibiting the NRF2-PD-L1 signal axis. All these findings may offer a novel strategy for enhancing anti-tumor immunity through regulating PD-L1, and provide a solid foundation for the clinical applications of MLT in combination with RFA therapy for lung cancer.

Melatonin Enhances the Remote Effect of Radiofrequency Ablation Via NRF-2 Mediated Inhibition of PD-L1 Transcription in Non-Small Cell Lung Cancer